Attached files
| file | filename |
|---|---|
| S-1/A - AMENDMENT NO. 2 TO FORM S-1 - TITAN PHARMACEUTICALS INC | tv502115-s1a.htm |
| EX-4.6 - EXHIBIT 4.6 - TITAN PHARMACEUTICALS INC | tv502115_ex4-6.htm |
| EX-1.1 - EXHIBIT 1.1 - TITAN PHARMACEUTICALS INC | tv502115_ex1-1.htm |
| EX-4.7 - EXHIBIT 4.7 - TITAN PHARMACEUTICALS INC | tv502115_ex4-7.htm |
| EX-5.1 - EXHIBIT 5.1 - TITAN PHARMACEUTICALS INC | tv502115_ex5-1.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference, in the Prospectus constituting a part of this Amendment No. 2 to Registration Statement on Form S-1 (No. 333-226841), of our report dated March 30, 2018, relating to the financial statements of Titan Pharmaceuticals, Inc., appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Our report contains an explanatory paragraph expressing substantial doubt about the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ OUM & CO. LLP
San Francisco, California
September 11, 2018